|
David Platt, Ph.D., is President, Chief Executive Officer and Chairman of the Board of Directors of Pro-Pharmaceuticals, Inc. (Amex: PRW), an early stage pharmaceutical company pioneering a paradigm shift in the way new drugs are designed by advancing Glycoscience. Dr. Platt co-founded the Company in 2000 and is a co-developer of its core nanotechnology, carbohydrate therapeutic compounds. From 1992 to 2000, Dr. Platt was a founder, CEO and Chairman of SafeScience, Inc., a biotechnology company involved in research and development of anti-angiogenesis products for treating cancer and immune system diseases. From 1991 to 1992, Dr. Platt was a research scientist with the Department of Internal Medicine at the University of Michigan, Ann Arbor, and from 1988 to 1990 was a research fellow at Wayne State University and the Michigan Cancer Foundation in Detroit (re-named Barbara Ann Karmanos Cancer Institute). Previously, Dr. Platt was a research fellow at the Weizmann Institute of Science, Rehovot, Israel. Dr. Platt received a Ph.D. in chemistry from Hebrew University in Jerusalem. Dr. Platt earned a Bachelor of Engineering degree from Technion in Haifa, Israel. Dr. Platt has published peer review articles and holds many patents, primarily in the field of carbohydrate chemistry. Dr. Platt co-edited and co-authored a new book Carbohydrate Drug Design” published by the American Chemical Society.
| 